Rigel Pharmaceuticals, Inc.
350 articles with Rigel Pharmaceuticals, Inc.
-
Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
12/5/2018
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
-
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
11/6/2018
Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million
-
Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition
11/1/2018
Data related to fostamatinib accepted for oral presentation and two poster presentations
-
Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results
10/30/2018
Rigel Pharmaceuticals, Inc. today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6, 2018.
-
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
10/29/2018
Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries.
-
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
10/11/2018
First SYK inhibitor for the treatment of adult chronic ITP
-
Rigel to Present at the Cantor Global Healthcare Conference
9/24/2018
The company's president and chief executive officer is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City on Wednesday, October 3, 2018 at 1:05pm EDT.
-
Rigel to Present at the 20th Annual Global Investment Conference in New York City
8/29/2018
Rigel Pharmaceuticals, Inc. today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference
-
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update
8/8/2018
$1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate)
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results
8/1/2018
Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.
-
Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
6/26/2018
Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.
-
US Bioservices Selected by Rigel Pharmaceuticals, Inc. to Dispense TAVALISSE™ (fostamatinib disodium hexahydrate) Tablets
6/18/2018
New therapy FDA-approved for adult patients with chronic immune thrombocytopenia
-
Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
6/12/2018
Rigel Pharmaceuticals, Inc. announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at the 23rd Congress of the European Hematology Association (EHA)
-
Rigel to Present at Jefferies 2018 Global Healthcare Conference
5/31/2018
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference.
-
Rigel Appoints Dean Schorno as Chief Financial Officer
5/30/2018
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).
-
Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
5/29/2018
Rigel Pharmaceuticals, Inc. announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients.
-
Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
5/1/2018
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2018.
-
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
4/30/2018
Phase 3 clinical program of TAVALISSE™ for the treatment of adults with chronic immune thrombocytopenia.
-
Rigel Announces Proposed Public Offering 15,000,000 Of Common Stock
4/18/2018
Rigel Pharmaceuticals, Inc. announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering.
-
Shares of Rigel Pharmaceuticals shot up about 40 percent during Thursday trading due primarily to an error on the company’s website that claimed its drug candidate Tavalisse had gained approval from the U.S. Food and Drug Administration (FDA).